ABI
MNK

Adamant Biomedical Investments’s MALLINCKRODT PUBLIC LIMITED COMPANY MNK Stock Holding History

Adamant Biomedical Investments’s Portfolio MNK Stock Details MNK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$7.92M Hold
80,000
– – 1.89% 15
2014
Q3 		$7.21M Buy
+80,000
New +$6.26M 1.8% 16

Other funds holding MNK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

Adamant Biomedical Investments's MNK Position: Q4 2014 in Review

Adamant Biomedical Investments held its MALLINCKRODT PUBLIC LIMITED COMPANY (MNK) position steady in Q4 2014 at 80,000 shares worth $7.92M. The position accounts for 1.89% of the portfolio, ranked #15.

Adamant Biomedical Investments first reported a position in MNK in Q3 2014 and has held it in 2 quarters since. 460 funds tracked by Wall St. Rank hold MNK as of Q4 2014.

  • Adamant Biomedical Investments held 80,000 shares of MALLINCKRODT PUBLIC LIMITED COMPANY worth $7.92M as of Q4 2014.
  • Adamant Biomedical Investments left its MALLINCKRODT PUBLIC LIMITED COMPANY share count unchanged in Q4 2014.
  • MALLINCKRODT PUBLIC LIMITED COMPANY made up 1.89% of Adamant Biomedical Investments's portfolio in Q4 2014, its #15 holding.
  • Adamant Biomedical Investments first reported a position in MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2014 and has held it in 2 quarters since.
  • 460 funds tracked by Wall St. Rank held MALLINCKRODT PUBLIC LIMITED COMPANY as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.